Naivek, Outstanding Efficacy of 'Peptide Anticancer Drug' Jointly Developed with Global Big Pharma

[Asia Economy Reporter Hyunseok Yoo] Naivek, a bio-specialized company with peptide fusion technology, announced research results at the JP Morgan Healthcare Conference showing that an anticancer drug under development with a global big pharma demonstrated outstanding efficacy, reducing tumor size by more than 90%. This announcement marks the beginning of full-scale joint research and development of anticancer drugs between Naivek and the global big pharma.

On the 13th, Naivek revealed that through joint research with a global big pharma, it verified that the anticancer drug under development showed not only excellent efficacy but also high safety in allogeneic transplantation animal model experiments.

The ‘allogeneic transplantation tumor model’ conducted this time is a more advanced level of experiment compared to previous validation tests. Naivek verified the safety and efficacy of the anticancer drug targeting 'mutated K-RAS,' known as a major cause of cancer cell proliferation.

Naivek applied the allogeneic transplantation animal model to study the efficacy of its self-developed ‘peptide fusion K-RAS inhibitory therapy’ based on its drug delivery platform. The research results showed that compared to the untreated animal control group, tumor size decreased by more than 90%, and survival was extended by up to about 35 days, whereas the control group died within 40 days, confirming excellent anticancer effects.

Additionally, a single intravenous injection maintained efficacy for about 48 hours without observing side effects caused by the administered drug. This verified the effective drug delivery capability and excellent targeting ability, where the drug is delivered only to the targeted organ without entering other body organs. This implies that the anticancer drug under development can exhibit greater efficacy not only as a monotherapy but also when combined with existing anticancer agents.

A Naivek official stated, “This study is a follow-up to the efficacy evaluation conducted through the previously performed ‘isogeneic transplantation tumor model.’ Generally, animal experiments use the isogeneic transplantation tumor model, which induces tumors in the hip area of rats for observation. However, for more accurate efficacy and safety testing, the allogeneic transplantation tumor model was applied, inducing tumors in organs where cancer occurs, such as the lungs or liver, rather than the hip. This model is technically more challenging than the isogeneic transplantation tumor model.”

He added, “Naivek confirmed that most drugs administered in the allogeneic transplantation tumor model were present in lung cancer tissues, proving that the selective drug delivery of our drug delivery platform NIPEP-TPP can be practically applied to lung cancer. Since tumor size reduction and survival rate were confirmed in actual lung cancer induced in the animal’s lungs, global big pharma is paying close attention to the results of the allogeneic transplantation model. This is significant both internally and externally, and based on these experimental results, joint research with global big pharma is expected to gain further momentum.”